Search results
Earnings call: Verona Pharma reports Q1 2024 results, eyes COPD market By Investing.com
Investing.com· 6 days agoVerona Pharma (NASDAQ:VRNA) has announced its first quarter 2024 financial results, highlighting the...
Sanofi to make €1bn biomanufacturing investment in France
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe...biologics currently in development, targeting diseases such as chronic obstructive pulmonary...
Raleigh pharma secures $650M to be ready for growth surge - Triangle Business Journal
The Business Journals· 7 days agoWith a potential regulatory approval more than a month away, a biopharmaceutical company in Raleigh...
Three-time cancer survivor starts nonprofit, provides meals for seniors
The Star via Yahoo News· 2 hours agoHillman said she went through her cancer treatments during COVID-19. “It was a lot of fear, a lot of...
Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial
Guru Focus· 6 days agoThe biopharmaceutical company, which focuses on developing treatments for respiratory diseases, reported a net loss and detailed its strategic preparations for the anticipated ...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 19 hours agoThe company is working on a drug to treat liver fibrosis due to hepatitis B and metabolic...
The Assistance Fund Opens New Program for Chronic Obstructive Pulmonary Disease
Digital Journal· 3 days agoThe program is designed to help eligible individuals pay for their out-of-pocket medical costs for treatment, such as copays, coinsurance, and deductibles. Chronic obstructive ...
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Verona...
Benzinga· 7 days agoPDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /
Sanofi boosts French biomanufacturing with €1 billion investment By Investing.com
Investing.com· 3 days agoSanofi (NASDAQ:SNY), a global biopharmaceutical company, announced today a significant investment of...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for...
WKBN 27 Youngstown· 21 hours agoOrally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed ...